Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897084057> ?p ?o ?g. }
- W2897084057 endingPage "393" @default.
- W2897084057 startingPage "385" @default.
- W2897084057 abstract "Four bichromophoric cyclometalated iridium complexes were synthesized and fully characterized. Their antiproliferative capacity against A549, HepG2 cells and HeLa cells as well as two human normal cells was studied by MTT assay. Rhodamine B modified complexes 2 and 4 were not cytotoxic to A549 cells while both rhodamine 6 g modified complexes 1 and 3 showed greater cytotoxicity than cisplatin. In particular, the antiproliferative activity of complex 3 was about 4.6 times than that of cisplatin. Thus, complex 3 was used for stability and pH sensitivity studies. The results indicated that the complex not only had rich fluorescence properties under acidic conditions, but also showed good stability. Further, interaction of complex with bovine serum albumin (BSA) has been investigated by UV−vis, fluorescence, synchronous fluorescence spectroscopy. The complexes have a certain ability to bind the BSA. Interestingly, these complexes can catalyze the reaction of the coenzyme NADH to NAD+, which is consistent with the apparent growth of ROS in cells. In addition, complex 3 can cause S phase arrest in the cell cycle, induce apoptosis, and affect mitochondrial membrane potential changes. Localization experiments of intracellular complexes by confocal microscopy suggested that these complexes enter cancer cells through energy dependence and specifically target the lysosomes, thus resulting in the damage of lysosomes." @default.
- W2897084057 created "2018-10-26" @default.
- W2897084057 creator A5002390407 @default.
- W2897084057 creator A5018818729 @default.
- W2897084057 creator A5020985791 @default.
- W2897084057 creator A5051683682 @default.
- W2897084057 creator A5065312383 @default.
- W2897084057 creator A5075479197 @default.
- W2897084057 creator A5091161457 @default.
- W2897084057 date "2019-03-01" @default.
- W2897084057 modified "2023-10-16" @default.
- W2897084057 title "Bichromophoric anticancer drug: Targeting lysosome with rhodamine modified cyclometalated Iridium(III) complexes" @default.
- W2897084057 cites W1892570967 @default.
- W2897084057 cites W1968635896 @default.
- W2897084057 cites W1980696498 @default.
- W2897084057 cites W1981101497 @default.
- W2897084057 cites W1982859999 @default.
- W2897084057 cites W1994367189 @default.
- W2897084057 cites W1996868772 @default.
- W2897084057 cites W1999071676 @default.
- W2897084057 cites W2012437459 @default.
- W2897084057 cites W2013597341 @default.
- W2897084057 cites W2026875674 @default.
- W2897084057 cites W2029540690 @default.
- W2897084057 cites W2033419889 @default.
- W2897084057 cites W2040403120 @default.
- W2897084057 cites W2045949658 @default.
- W2897084057 cites W2046107966 @default.
- W2897084057 cites W2047001506 @default.
- W2897084057 cites W2051958858 @default.
- W2897084057 cites W2069729331 @default.
- W2897084057 cites W2071204513 @default.
- W2897084057 cites W2075385784 @default.
- W2897084057 cites W2076984688 @default.
- W2897084057 cites W2080244715 @default.
- W2897084057 cites W2082082766 @default.
- W2897084057 cites W2085625844 @default.
- W2897084057 cites W2094691730 @default.
- W2897084057 cites W2113689159 @default.
- W2897084057 cites W2116551031 @default.
- W2897084057 cites W2147622657 @default.
- W2897084057 cites W2166284450 @default.
- W2897084057 cites W2167574366 @default.
- W2897084057 cites W2171890092 @default.
- W2897084057 cites W2282989227 @default.
- W2897084057 cites W2317574010 @default.
- W2897084057 cites W2333429831 @default.
- W2897084057 cites W2343860076 @default.
- W2897084057 cites W2413990098 @default.
- W2897084057 cites W2525804344 @default.
- W2897084057 cites W2564885729 @default.
- W2897084057 cites W2571986219 @default.
- W2897084057 cites W2596392962 @default.
- W2897084057 cites W2603374409 @default.
- W2897084057 cites W2605048423 @default.
- W2897084057 cites W2614925003 @default.
- W2897084057 cites W2616913617 @default.
- W2897084057 cites W2748786904 @default.
- W2897084057 cites W2762095400 @default.
- W2897084057 cites W2765260259 @default.
- W2897084057 cites W2766433125 @default.
- W2897084057 cites W2768065106 @default.
- W2897084057 cites W2769971892 @default.
- W2897084057 cites W2773553370 @default.
- W2897084057 cites W2787263985 @default.
- W2897084057 cites W2796274384 @default.
- W2897084057 cites W2804136272 @default.
- W2897084057 cites W2809901665 @default.
- W2897084057 cites W2885264971 @default.
- W2897084057 cites W2885656034 @default.
- W2897084057 cites W2888202543 @default.
- W2897084057 cites W2888526454 @default.
- W2897084057 cites W2888895093 @default.
- W2897084057 cites W2889006785 @default.
- W2897084057 cites W2892098340 @default.
- W2897084057 cites W2899500557 @default.
- W2897084057 cites W2949558574 @default.
- W2897084057 cites W2951483887 @default.
- W2897084057 doi "https://doi.org/10.1016/j.dyepig.2018.10.019" @default.
- W2897084057 hasPublicationYear "2019" @default.
- W2897084057 type Work @default.
- W2897084057 sameAs 2897084057 @default.
- W2897084057 citedByCount "38" @default.
- W2897084057 countsByYear W28970840572019 @default.
- W2897084057 countsByYear W28970840572020 @default.
- W2897084057 countsByYear W28970840572021 @default.
- W2897084057 countsByYear W28970840572022 @default.
- W2897084057 countsByYear W28970840572023 @default.
- W2897084057 crossrefType "journal-article" @default.
- W2897084057 hasAuthorship W2897084057A5002390407 @default.
- W2897084057 hasAuthorship W2897084057A5018818729 @default.
- W2897084057 hasAuthorship W2897084057A5020985791 @default.
- W2897084057 hasAuthorship W2897084057A5051683682 @default.
- W2897084057 hasAuthorship W2897084057A5065312383 @default.
- W2897084057 hasAuthorship W2897084057A5075479197 @default.
- W2897084057 hasAuthorship W2897084057A5091161457 @default.
- W2897084057 hasConcept C109316439 @default.
- W2897084057 hasConcept C121332964 @default.